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Abstract
OBJECTIVE: To assess the efficacy of Huangshukui-
hua (Flos Abelmoschi Manihot) on diabetic nephrop-
athy (DN).
METHODS: Articles were retrieved from PubMed,
EMBASE, the Cochrane Central Register of Con-
trolled Trials, Web of Science, Chinese Biomedical
Literature Database, and China National Knowl-
edge Infrastructure Database, Chinese Evi-
dence-Based Medicine Database, and Wanfang Da-
tabase. Two reviewers independently reviewed the
article. Only randomized controlled trials were in-
cluded and 27 were identified involving 2239 pa-
tients (1143 in the treatment group and 1096 in the
control group).
RESULTS: Huangshukuihua (Flos Abelmoschi Mani-
hot) had a significant effect on renal function by im-
proving blood urea nitrogen and serum creatinine,
reducing urine protein (24-h urine protein, and uri-
nary albumin excretion rate), and improving serum
albumin level, compared with the control group.
CONCLUSION: Our findings suggest that, although
the bioactive ingredients and mechanism underly-
ing renal protection are unknown, the role of
Huangshukuihua (Flos Abelmoschi Manihot) in the
treatment of DN deserves further investigation.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Diabetic nephropathy (DN) is one of the common
chronic complications of diabetes. Without active treat-
ment, DN eventually develops into end stage renal dis-
eases (ESRD), which occurs in 20%-40% diabetic pa-
tients.1 In Western countries, DN ranks the first
among the primary etiologies leading to ESRD, ac-
counting for about 37%-40%.2 In China, about 30%
of type 1 and 20% of type 2 diabetes develop into DN,
and 53% of the patients die from diabetic renal failure.3
With Centuries of clinical experience with chronic kid-
ney disease (CKD) and DN, Chinese clinicians and
practitioners have developed treatments to combat the
diseases. The "Noinclude," an ancient book containing
records of Traditional Chinese Medicine (TCM), indi-
cates that TCM has been used to treat CKD and DN
in China since at least 475 BCE. Today, TCM are still
used extensively for the treatment of CKD and DN in
China. Huangshukuihua (Flos Abelmoschi Manihot) is
used to treat kidney disease and infection of skin and
mucous membrane. The treatment was first document-
ed in Jia You Ben Cao, a Traditional Chinese Medical
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book written in 1060 AD.4 Huangshukuihua (Flos Abel-
moschi Manihot) is in the same family as okra, Malvace-
ae, and is found in Vietnam, Laos, Cambodia, Thai-
land, India, and China. Huangshukuihua (Flos Abelmos-
chi Manihot), it is widely grown in southern China.
The major pharmacologically active constituents of
Huangshukuihua (Flos Abelmoschi Manihot) are the to-
tal flavones of Abelmoschus manihot (L.) Medicus (Hi-
biscus manihot L.) (TFA).5,6 The chemical constituents
of TFA have been isolated, and their structures have
been identified by spectroscopic analysis. TFA contains
seven flavone glycosides, including myricetin, hyperin,
quercetin, quercetin-3'-β-glucoside, hibiscetin-3-O-
glucoside, myricetin-3-O-glucoside, and gossype-
tin-8-O-β-D-glucuronide. However, it is still not clear
which chemical component is responsible for the ex-
tract's renoprotective effect. Therefore, researchers com-
monly use okra capsules [its main component is
Huangshukuihua (Flos Abelmoschi Manihot)] in phar-
macodynamic and pharmacological studies.7
Many clinical trials have reported that Huangshukui-
hua (Flos Abelmoschi Manihot) ameliorates DN by me-
diating serum glucose and lipid metabolism through a
caspase-dependent pathway.7 However, the efficacy of
Huangshukuihua (Flos Abelmoschi Manihot) is unclear
owing to the lack of high-quality, large-sample random
clinical trials. Therefore, we systematically reviewed the
randomized control trials to evaluate the efficacy of
Huangshukuihua (Flos Abelmoschi Manihot) in the
treatment of DN.
MATERIALS ANDMETHODS
Search strategy
Databases were searched by electronic and manual
methods, including PubMed, EMBASE, the Cochrane
Central Register of Controlled Trials , Web of Science,
Chinese Biomedical Literarure Database, China Na-
tional Knowledge Infrastructure Database, Chinese Evi-
dence-Based Medicine Database, Wanfang Database
and hand-searching of reference which don't include
these electronic databases noted above.
Different search strategies performed are as follows.
For English databases, we used free text terms as "Abel-
moschus manihot" or "Okra" and "diabetic nephropa-
thy." For Chinese databases, we used free text terms as
"Huang Shu Kui" or "Huang Kui" (which is the alter-
native name of Abelmoschus manihot in Chinese), and
"Tang Niao Bing Shen Bing" (which means diabetic ne-
phropathy in Chinese). A filter for clinical trials was ap-
plied. We also attempted to identify additional studies
by searching the reference lists of included trials.
Selection criteria
All randomized control trials (RCTs) were included re-
gardless of language. Patients met the diagnostic crite-
ria for diabetic mellitus [World Health Organization
(WHO)-1999, The American Diabetes Association
(ADA)-1997]. Patients in the clinic stageⅢ-Ⅳ of DN
were included according to the Mogensen DN diagnos-
tic criteria.8 Patients with other chronic diseases (chron-
ic heart disease, chronic liver disease, chronic respirato-
ry disease, tumor, autoimmunity disease, infection dis-
ease) were excluded.
Methodological quality appraisal
The capsule of Huangshukuihua (Flos Abelmoschi
Manihot) was prepared by Szzy Group pharmaceutical
Limited (Jiangsu, China) according to the quality stan-
dard of China State Food and Drug Administration.
The main components of Huangshukuihua capsule
were the total flavonoids extracted from the flowers of
Abelmoschus manihot (L.) Medicus (Hibiscus manihot
L.). The capsules were administrated orally. The dosage
was 2.5 mg/d and the treatment course ranged from 8
to 24 weeks.
Data extraction and criteria of therapeutic effects
Important data from the primary studies were extract-
ed: the number of patients in treatment group and the
control group, age, gender, history of DM, interven-
tion, treatment duration, and the use of ACE inhibitor
or angiotensin receptor blocker (ARB). Data in the
Huangshukuihua capsule treatment group were
matched with the data in the control group.
Criteria of therapeutic effects included serum albumin,
renal function [blood urea nitrogen (BUN), serum cre-
atinine (SCr)], and urine protein such as 24-h urine
protein and urinary albumin excretion rate (UAER).
Assessment method
Two assessors (Sun Qin and Yang Gangyi) indepen-
dently reviewed each study, and disagreements were
resolved by consensus. The following information
was extracted: randomization process, allocation con-
cealment, blinding, participant dropout and loss to
follow up, intention-to-treat analysis, and explicit di-
agnostic and outcome criteria. The trials were coded
as A: adequate; B: unclear; or C: inadequate, accord-
ing to the Cochrane Handbook for Systematic Re-
views.9
Statistical methods
Meta-analysis was conducted using Rev Man 5.2. (Co-
chrane collaboration, Oxford, UK).10 Estimated effect
of data was calculated by standardized mean difference
(SMD) or weight mean difference (WMD). Chi-square
test was used for heterogeneity. We tested heterogene-
ity using the I 2 statistic with significance set at 50% ,
and the Chi2 statistic with significance set at P < 0.10.
If significant heterogeneity was identified, the ran-
dom-effects model was used. Trials showing clinical het-
erogeneity were combined according to the random ef-
fect model and the remaining studies used the fixed ef-
fect model.11
16
JTCM |www. journaltcm. com February 15, 2015 |Volume 35 | Issue 1 |
Sun Q et al. / Systematic Review
RESULTS
Description of studies
Overall, 89 studies including 27 RCTs were eligible
(Figure 1).1,12-37 The included studies are summarized in
Table 1 and Table 2. A total of 2239 patients were en-
rolled for analysis of effectiveness (1143 in the treat-
ment group and 1096 in the control group). All stud-
ies were carried out in the People's Republic of China
and all patients involved in the trials were Chinese.
Data analysis
BUN: a total of 13 RCTs16,18,20,22,23,27,28,30,31,33-35,37 (502 pa-
tients in treatment group and 492 in the control
group) were conducted to analyze serum urea nitrogen.
Figure 2 shows the forest plot for BUN comparison.
The results show that patients in the Huangshukui-
hua group had significantly lower BUN levels than
those in the control group [SMD = ﹣0.44 (﹣0.57,
﹣ 0.32), P < 0.000 01 ], which suggests a moderate
heterogeneity.
SCr: nineteen trials12,13,15,16,18-20,22-24,27-32,33,34,37 evaluated the
efficacy of Huangshukuihua (Flos Abelmoschi Manihot)
on SCr in the treatment group compared with the con-
trol group. There were 724 patients in the treatment
group and 700 in the control group. Because of signifi-
cant heterogeneity, we chose the random effect model.
Figure 3 shows the forest plots for the outcome mea-
sures. [SMD = ﹣0.71 (﹣1.09, ﹣0.32), P = 0.0004].
Compared with the control group, the Huangshukui-
hua group had significantly lower SCr.
24-h Urine Protein: eighteen RCTs12, 14-19, 23-25, 27, 29-32, 34, 35, 37
(803 patients in the treatment group and 773 in the
control group) analyzed the 24-h urine protein. Figure 4
shows the forest plot for the 24-h urine protein compari-
son. The results show that the Huangshukuihua group
had significantly lower 24-h urine protein compared
with the control group [SMD = ﹣0.87; 95% CI: (﹣
1.14,﹣0.61); P < 0.000 01].
UAER: eight RCTs12,21,22,25,26,34-36 evaluated the UAER of
the treatment group as compared with the control
group. There were 350 patients in the treatment group
and 324 in the control group. The trials showed clini-
cal heterogeneity and were combined according to the
Figure 2 Effect of Abelmoschus manihot on blood urea nitrogen in diabetic nephropathy patients
Figure 1 Flow diagram of literature search
CCT: controlled clinical trial; UOS: uncontrolled observational study; RCTs: randomized controlled trials
82 articles identified through database
searching
7 additional articles identified
through hand-searching
89 articles screened
48 articles excluded on the
basis of title and abstract
41 full-text articles
Assessed for eligibility
14 full-text articles excluded:
CCT (n = 2)
UOS (n = 12)
27 RCTs qualified
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random effect model. Figure 5 shows the forest plots
for the outcome measures. [SMD =﹣1.04 (﹣1.34,﹣
0.75), P < 0.000 01]. Compared with the control
group, the Huangshukuihua group had significantly
lower UAER.
Serum albumin: four clinical trials24,28,30,32 evaluated the
serum albumin of the treatment group as compared
with the control group. There were 128 patients in the
treatment group and 126 in the control group. Figure
6 shows the forest plots for the outcome measures.
[SMD = 0.25 (0.01, 0.50), P = 0.04]. Compared with
the control group, the Huangshukuihua group had sig-
nificantly higher serum albumin levels. The effect was
homogeneous.
Adverse effects: we did not conduct analysis on adverse
effect because of the lack of reports on severe side ef-
fects in all the clinical trials involved.
DISCUSSION
This Meta-analysis provides a quantitative evaluation
of the clinical effect of Huangshukuihua (Flos Abelmos-
chi Manihot) on DN by integrating outcomes from 27
clinical studies that include 1143 treatment patients
and 1096 control patients. Our results show that the
levels of BUN and SCr were significantly lower in the
treatment group compared with the control group,
which suggests a protective effect of Huangshukuihua
(Flos Abelmoschi Manihot) on renal function in DN pa-
tients.
Abdominal distension and other gastrointestinal symp-
toms might occur after taking the capsule, but the
symptoms were mild, and symptoms disappeared when
medication was adjusted to the postprandial period.
No studies indicated that patients discontinued treat-
Figure 3 Effect of Abelmoschus manihot on serum creatinine in diabetic nephropathy patients
Figure 4 Effect of Abelmoschus manihot on 24-h urine protein in diabetic nephropathy patients
18
JTCM |www. journaltcm. com February 15, 2015 |Volume 35 | Issue 1 |
Sun Q et al. / Systematic Review
ment because of side effects. This Meta-analysis could
not carry out a systematic review on adverse effects be-
cause of the lack of reporting on severe side effects in
all the clinical trials involved.
The findings of our Meta-analysis demonstrate that
Huangshukuihua (Flos Abelmoschi Manihot) treats DN
patients by improving renal function and reducing
urine protein.
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